Horm Metab Res 2024; 56(03): 244-254
DOI: 10.1055/a-2184-8945
Original Article: Endocrine Research

LncRNA LINC01339 Hinders the Development of Wilms’ Tumor via MiR-135b-3p/ADH1C Axis

Yang Yu
1   Department of Nephrology, Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, China
,
Yanfei Liu
2   Department of Oncology, Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, China
› Institutsangaben

Abstract

Wilms’ tumor is a malignant renal cancer that arises within the pediatric urinary system. This study intended to investigate how a novel long non-coding RNA LINC01339 functions in the pathogenesis of Wilms’ tumor. An elevated miR-135b-3p expression as well as reduced levels of LINC01339 and ADH1C were observed in Wilms’ tumor. LINC01339 mediated ADH1C expression by directly binding to miR-135b-3p. The enforced LINC01339 or ADH1C markedly hindered cell growth and migration in Wilms’ tumor. The LINC01339 overexpression also repressed the growth of Wilms’ tumors in vivo, whereas miR-135b-3p overexpression exerted the opposite effects on Wilms’ tumor cells in vitro. Additionally, upregulating miR-135b-3p reversed LINC01339’s effects on the cellular processes of Wilms’ tumor cells, whereas ADH1C overexpression offset the cancer-promoting influence of miR-135b-3p upregulation on Wilms’ tumor progression. Therefore, LINC01339 prevents Wilms’ tumor progression by modulating the miR-135b-3p/ADH1C axis. Our findings substantiate that the LINC01339/miR-135 b-3p/ADH1C regulatory axis has potential to be a target for the treatment of Wilms’ tumor.

Supplementary Material



Publikationsverlauf

Eingereicht: 01. Juni 2023

Angenommen nach Revision: 26. September 2023

Artikel online veröffentlicht:
27. Oktober 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Lopes RI, Lorenzo A. Recent advances in the management of Wilmsʼ tumor. F1000Res 2017; 6: 670
  • 2 John R, Kurian JJ, Sen S. et al. Clinical outcomes of children with Wilms tumor treated on a SIOP WT 2001 protocol in a tertiary care hospital in south India. J Pediatr Urol 2018; 14: 547.e541-547.e547
  • 3 Cone EB, Dalton SS, Van Noord M. et al. Biomarkers for Wilms tumor: a systematic review. J Urol 2016; 196: 1530-1535
  • 4 Qi C, Hu Y, Yang F. et al. Preliminary observations regarding the expression of collagen triple helix repeat-containing 1 is an independent prognostic factor for Wilms' tumor. J Pediatr Surg 2016; 51: 1501-1506
  • 5 Brok J, Pritchard-Jones K, Geller JI. et al. Review of phase I and II trials for Wilms' tumour – Can we optimise the search for novel agents?. Eur J Cancer 2017; 79: 205-213
  • 6 Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 2013; 12: 847-865
  • 7 Felekkis K, Touvana E, Stefanou C. et al. microRNAs: a newly described class of encoded molecules that play a role in health and disease. Hippokratia 2010; 14: 236-240
  • 8 Luo B, Ma L, Xing X. et al. MiR-22-3p regulates the proliferation and invasion of Wilmsʼ tumor cells by targeting AKT3. Eur Rev Med Pharmacol Sci 2020; 24: 5996-6004
  • 9 Luo X, Dong J, He X. et al. MiR-155-5p exerts tumor-suppressing functions in Wilms tumor by targeting IGF2 via the PI3K signaling pathway. Biomed Pharmacother 2020; 125: 109880
  • 10 Li H, Wang X. Expression of miR-140-5p and miR-370 in nephroblastoma and its effect on cell proliferation. J Buon 2020; 25: 2105-2109
  • 11 An NN, Shawn J, Peng JP. et al. Up-regulation of miR-190b promoted growth, invasion, migration and inhibited apoptosis of Wilms' tumor cells by repressing the PTEN expression. Eur Rev Med Pharmacol Sci 2018; 22: 961-969
  • 12 Che G, Gao H, Tian J. et al. MicroRNA-483-3p promotes proliferation, migration, and invasion and induces chemoresistance of Wilmsʼ tumor cells. Pediatr Dev Pathol 2020; 23: 144-151
  • 13 Ghafouri-Fard S, Vafaee R, Shoorei H et al. MicroRNAs in gastric cancer: Biomarkers and therapeutic targets. Gene 2020; 757: 144937
  • 14 Bao C, Lu Y, Chen J. et al. Exploring specific prognostic biomarkers in triple-negative breast cancer. Cell Death Dis 2019; 10: 807
  • 15 Nuñez-Sánchez MA, Dávalos A, González-Sarrías A. et al. MicroRNAs expression in normal and malignant colon tissues as biomarkers of colorectal cancer and in response to pomegranate extracts consumption: Critical issues to discern between modulatory effects and potential artefacts. Mol Nutr Food Res 2015; 59: 1973-1986
  • 16 Wang L, Zhu MJ, Ren AM. et al. A ten-microRNA signature identified from a genome-wide microRNA expression profiling in human epithelial ovarian cancer. PLoS One 2014; 9: e96472
  • 17 Zhao H, Wang P, Wang G. et al. A long non-coding RNAs expression signature to improve prognostic prediction of Wilms tumor in children. Transl Pediatr 2021; 10: 525-540
  • 18 Yao FZ, He R, Jiang YC. et al. LncRNA XIST promotes migration of Wilms' tumor cells through modulation of microRNA-193a-5p. Eur Rev Med Pharmacol Sci 2020; 24: 9889-9898
  • 19 Cui WW, Sun YL, Chen C. et al. LncRNA CRNDE promotes the development of Wilms' tumor by regulating microRNA-424. Eur Rev Med Pharmacol Sci 2020; 24: 1088-1097
  • 20 Zheng H, Li BH, Liu C. et al. Comprehensive analysis of lncRNA-mediated ceRNA crosstalk and identification of prognostic biomarkers in Wilms' tumor. Biomed Res Int 2020; 2020: 4951692
  • 21 Zhang F, Zeng L, Cai Q. et al. Comprehensive analysis of a long noncoding RNA-associated competing endogenous RNA network in Wilms tumor. Cancer Control 2020; 27: 1073274820936991
  • 22 He X, Luo X, Dong J. et al. Long non-coding RNA XIST promotes Wilms tumor progression through the miR-194-5p/YAP axis. Cancer Manag Res 2021; 13: 3171-3180
  • 23 Su L, Wu A, Zhang W. et al. Silencing long non-coding RNA SNHG6 restrains proliferation, migration and invasion of Wilmsʼ tumour cell lines by regulating miR-15a. Artif Cells Nanomed Biotechnol 2019; 47: 2670-2677
  • 24 Liu P, Chen S, Huang Y. et al. LINC00667 promotes Wilmsʼ tumor metastasis and stemness by sponging miR-200b/c/429 family to regulate IKK-β. Cell Biol Int 2020; 44: 1382-1393
  • 25 Seitz HK, Stickel F. Acetaldehyde as an underestimated risk factor for cancer development: role of genetics in ethanol metabolism. Genes Nutr 2010; 5: 121-128
  • 26 Offermans NSM, Ketcham SM, van den Brandt PA. et al. Alcohol intake, ADH1B and ADH1C genotypes, and the risk of colorectal cancer by sex and subsite in the Netherlands cohort study. Carcinogenesis 2018; 39: 375-388
  • 27 Mohelnikova-Duchonova B, Vrana D, Holcatova I. et al. CYP2A13, ADH1B, and ADH1C gene polymorphisms and pancreatic cancer risk. Pancreas 2010; 39: 144-148
  • 28 Chang JS, Straif K, Guha N. The role of alcohol dehydrogenase genes in head and neck cancers: a systematic review and meta-analysis of ADH1B and ADH1C. Mutagenesis 2012; 27: 275-286
  • 29 Ji YB, Lee SH, Kim KR. et al. Association between ADH1B and ADH1C polymorphisms and the risk of head and neck squamous cell carcinoma. Tumour Biol 2015; 36: 4387-4396
  • 30 Hidaka A, Sasazuki S, Matsuo K. et al. Genetic polymorphisms of ADH1B, ADH1C and ALDH2, alcohol consumption, and the risk of gastric cancer: the Japan public health center-based prospective study. Carcinogenesis 2015; 36: 223-231
  • 31 Abbo O, Pinnagoda K, Brouchet L. et al. Wilms tumor, pleuropulmonary blastoma, and DICER1: case report and literature review. World J Surg Oncol 2018; 16: 164
  • 32 Flores P, Cadario M, Lenz Y. et al. Laparoscopic total nephrectomy for Wilms tumor: Towards new standards of care. J Pediatr Urol 2018; 14: 388-393
  • 33 Liu Q. The emerging landscape of long non-coding RNAs in Wilms tumor. Front Oncol 2021; 11: 780925
  • 34 Wang Y, Liu J, Yao Q. et al LncRNA SNHG6 promotes Wilmsʼ tumor progression through regulating miR-429/FRS2 axis. Cancer Biother Radiopharm 2021; DOI: 10.1089/cbr.2020.3705.
  • 35 Zhao XS, Tao N, Zhang C. et al. Long noncoding RNA MIAT acts as an oncogene in Wilms' tumor through regulation of DGCR8. Eur Rev Med Pharmacol Sci 2021; 25: 6160
  • 36 Teng GY, Wang YJ, Geng M. et al. LncRNA MEG3 inhibits the growth, invasion and migration of Wilms' tumor via Wnt/β-catenin pathway. Eur Rev Med Pharmacol Sci 2020; 24: 9899-9907
  • 37 Wang Y, Wang Z, Shao C. et al. Melatonin may suppress lung adenocarcinoma progression via regulation of the circular noncoding RNA hsa_circ_0017109/miR-135b-3p/TOX3 axis. J Pineal Res 2022; 73: e12813
  • 38 Zhu C, Wang S, Zheng M. et al. miR-31-5p modulates cell progression in lung adenocarcinoma through TNS1/p53 axis. Strahlenther Onkol 2022; 198: 304-314
  • 39 Bi J, Liu H, Cai Z. et al. Circ-BPTF promotes bladder cancer progression and recurrence through the miR-31-5p/RAB27A axis. Aging (Albany NY) 2018; 10: 1964-1976
  • 40 Peng W, Wu R, Dai W. et al. MiRNA-gene network embedding for predicting cancer driver genes. Brief Funct Genomics 2023; 22: 341-350
  • 41 Parizi PK, Yarahmadi F, Tabar HM. et al. MicroRNAs and target molecules in bladder cancer. Med Oncol 2020; 37: 118
  • 42 Li S, Yang H, Li W. et al. ADH1C inhibits progression of colorectal cancer through the ADH1C/PHGDH/PSAT1/serine metabolic pathway. Acta Pharmacol Sin 2022; 43: 2709-2722
  • 43 Jiang F, Shen Q, Zhang F. et al. ADH1C facilitates cisplatin resistance of lung adenocarcinoma cells. DNA Cell Biol 2022; 41: 631-640
  • 44 Zhu KR, Sun QF, Zhang YQ. Long non-coding RNA LINP1 induces tumorigenesis of Wilmsʼ tumor by affecting Wnt/β-catenin signaling pathway. Eur Rev Med Pharmacol Sci 2021; 25: 1763